Back to Search Start Over

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

Authors :
Sumana Chakravarty
Eric R. James
Stephen L. Hoffman
Lei K. Ding
Jillian Neal
Charles Wyatt
Sahand Kalhori
Anita Manoj
Alemush Imeru
Omely Marte-Salcedo
Sangeeta N. Bhatia
Hope Decederfelt
David M. Cook
Agnes Mwakingwe-Omari
Martha Nason
Jen C. C. Hume
Sara A. Healy
Aarti Kolluri
Natasha Kc
Ijeoma Ikpeama
B. Kim Lee Sim
Peter F. Billingsley
Sean C. Murphy
L. W. Preston Church
Jihyun E. Jeon
Sandra March
Grace K. Lee
Irfan Zaidi
Jacob Raiten
Junhui Duan
Anusha Gunasekera
Thomas L. Richie
Tooba Murshedkar
Jacquelyn Lane
Patrick E. Duffy
Charles Anderson
Source :
Nature. 595:289-294
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

The global decline in malaria has stalled1, emphasizing the need for vaccines that induce durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination (CVac), for which aseptic, purified, cryopreserved, infectious Plasmodium falciparum sporozoites (PfSPZ) were inoculated under prophylactic cover with pyrimethamine (PYR) (Sanaria PfSPZ-CVac(PYR)) or chloroquine (CQ) (PfSPZ-CVac(CQ))—which kill liver-stage and blood-stage parasites, respectively—and we assessed vaccine efficacy against homologous (that is, the same strain as the vaccine) and heterologous (a different strain) controlled human malaria infection (CHMI) three months after immunization ( https://clinicaltrials.gov/ , NCT02511054 and NCT03083847). We report that a fourfold increase in the dose of PfSPZ-CVac(PYR) from 5.12 × 104 to 2 × 105 PfSPZs transformed a minimal vaccine efficacy (low dose, two out of nine (22.2%) participants protected against homologous CHMI), to a high-level vaccine efficacy with seven out of eight (87.5%) individuals protected against homologous and seven out of nine (77.8%) protected against heterologous CHMI. Increased protection was associated with Vδ2 γδ T cell and antibody responses. At the higher dose, PfSPZ-CVac(CQ) protected six out of six (100%) participants against heterologous CHMI three months after immunization. All homologous (four out of four) and heterologous (eight out of eight) infectivity control participants showed parasitaemia. PfSPZ-CVac(CQ) and PfSPZ-CVac(PYR) induced a durable, sterile vaccine efficacy against a heterologous South American strain of P. falciparum, which has a genome and predicted CD8 T cell immunome that differs more strongly from the African vaccine strain than other analysed African P. falciparum strains. Two malaria vaccines comprising Plasmodium falciparum sporozoites and treatment with either pyrimethamine or chloroquine induced durable protective responses against both the African vaccine strain and a heterologous South American strain of P. falciparum.

Details

ISSN :
14764687 and 00280836
Volume :
595
Database :
OpenAIRE
Journal :
Nature
Accession number :
edsair.doi.dedup.....5683981db2e900df72762416f20eb4b7